Dr Bruce Chabner has had immense experience in the discipline of cancer drug discovery and development. During his career at the National Cancer Institute, he worked as a Senior Investigator in the Laboratory of Chemical Pharmacology, Chief of the Clinical Pharmacology Branch, Director of the Clinical Oncology Program, and Director of the Division of Cancer Treatment. His research significantly added to the development of high dose chemotherapy regimens and standard therapies for lymphoma. Additionally, his research led to the development of Taxol. He currently serves as a Professor of Medicine at Harvard Medical School and Director of Clinical Research at the MGH Cancer Center at Massachusetts General Hospital.